Despite efforts designed to suppress the expression and enzymatic activity of FAP as anti-cancer treatments, studies, such as those involving the development of a murine anti-FAP mAb F19 and its humanized version unconjugated sibrotuzumab (BIBH 1) (24–26), have failed to demonstrate promising clinical efficacy. The gene discussed is FAP; the disease is cancer.